Neutrophil Influx in Response to a Peritoneal Infection with Salmonella Is Delayed in Lipopolysaccharide-Binding Protein or CD14-Deficient Mice

Autor: Kk, Yang, Bg, Dorner, Merkel, U., Ryffel, Bernhard, Schütt, C., Golenbock, D., Mw, Freeman, Rs, Jack

Publikováno v: Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2002, 169, pp.4475-4480

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::022c6397c5fa124b1c7d2ce2634bd795
https://hal.archives-ouvertes.fr/hal-00095135

Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.

Autor: McMurray JJV; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK., Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lock JP; Diabetes Center of Excellence, Department of Medicine, University of Massachusetts, Worcester, Massachusetts, USA., Massaro JM; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA., Zhu F; Navitas Life Sciences, Princeton, New Jersey, USA., Zhou W; Hopkins Consulting LLC, Philadelphia, Pennsylvania, USA., Skali H; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lewis EF; Division of Cardiovascular Medicine, Stanford Health Care, Palo Alto, California, USA., Freeman MW; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, USA., Halvorsen YC; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Mar; Vol. 26 (3), pp. 971-979. Date of Electronic Publication: 2023 Dec 27.

Baxdrostat for Treatment-Resistant Hypertension. Reply.

Autor: Freeman MW; CinCor Pharma, Boston, MA., Halvorsen YD; CinCor Pharma, Boston, MA., Brown MJ; Queen Mary University of London, London, United Kingdom morris.brown@qmul.ac.uk.

Publikováno v: The New England journal of medicine [N Engl J Med] 2023 May 11; Vol. 388 (19), pp. 1821-1822.

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.

Autor: Freeman MW; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Halvorsen YD; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Marshall W; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Pater M; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Isaacsohn J; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Pearce C; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Murphy B; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Alp N; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Srivastava A; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Bhatt DL; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.)., Brown MJ; From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the Department of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London (M.J.B.).

Publikováno v: The New England journal of medicine [N Engl J Med] 2023 Feb 02; Vol. 388 (5), pp. 395-405. Date of Electronic Publication: 2022 Nov 07.

A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.

Autor: Halvorsen YD; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts., Lock JP; Theracos Sub, LLC, Marlborough, Massachusetts., Frias JP; Velocity Clinical Research, Los Angeles, California., Tinahones FJ; Hospital Virgen de la Victoria. Instituto de investigación Biomedica de Málaga IBIMA. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Málaga University, Málaga, Spain., Dahl D; Gemeinschaftspraxis fur lnnere Medizin und Diabetologie, Hamburg, Germany., Conery AL; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts., Freeman MW; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jan; Vol. 25 (1), pp. 293-301. Date of Electronic Publication: 2022 Oct 23.